Episode 4: Diagnosing NAFLD and NASH

Overview

In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode we’re talking about diagnosing NAFLD and NASH.

Learning Objectives

By the end of this podcast, listeners will be able to:

Describe noninvasive diagnostic techniques for patients at high risk for NASH
Understand when to refer a patient to a hepatologist
Understand the role of liver biopsy in diagnosing NASH

Key Takeaways

Patients determined to be at intermediate or high risk of NAFLD-related advanced fibrosis using simple non-invasive fibrosis scores may require a second-line test and/or referral to a hepatologist.
While no longer required to diagnose liver fibrosis and NASH in all cases, liver biopsy should be considered where there is diagnostic doubt.

CME

To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.

This activity is accredited through Sep. 30, 2022.

The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Credits

Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University

Guest: Vincent Wong, MD, The Chinese University of Hong Kong

Created by: Knighten Health, LLC

Produced and edited by: Nick Jaworksi

Cover art: THOR Design Studio

Disclosures

Fasiha Kanwal discloses no conflicts.

Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.

Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.

Vincent Wong served as a consultant or advisory board member for 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Center for Outcomes Research in Liver Diseases, Echosens, Gilead Sciences, Hanmi Pharmaceutical, Intercept, Inventiva, Merck, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions and Terns; and a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosens and Gilead Sciences. He has received a grant from Gilead Sciences for fatty liver research, and is a co-founder of Illuminatio Medical Technology Limited.

Sponsor

American Gastroenterological Association

Funding

This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.